Compare DRH & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRH | WGS |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | 35 | 1300 |
| Industry | Real Estate Investment Trusts | Retail: Computer Software & Peripheral Equipment |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | DRH | WGS |
|---|---|---|
| Price | $10.24 | $67.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $10.38 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 1.7M | 543.3K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.44 | $29.98 |
| Revenue Next Year | $2.42 | $25.92 |
| P/E Ratio | ★ $38.41 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $55.17 |
| 52 Week High | $10.68 | $170.87 |
| Indicator | DRH | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 50.43 |
| Support Level | $9.10 | $56.24 |
| Resistance Level | $10.65 | $73.46 |
| Average True Range (ATR) | 0.23 | 3.94 |
| MACD | -0.02 | 0.54 |
| Stochastic Oscillator | 32.31 | 53.61 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.